Effect of dietary omega-3 fatty acids on high-density lipoprotein apolipoprotein AI kinetics in type II diabetes mellitus

Atherosclerosis

Volumn 157, Issue 1, 2001, Pages 131-135

  Frenais R ^a   Ouguerram, K ^a   Maugeais, C ^a   Mahot, P ^b   Charbonnel, B ^b   Magot, T ^a   Krempf, M ^a,b  

^a INSERM   (France)

^b Clinique d'Endocrinologie Hotel Dieu CHU de Nantes   (France)

Author keywords

Apo AI; HDL; Kinetic; n 3 polyunsaturated acids; Type II diabetes mellitus

Indexed keywords

APOLIPOPROTEIN A1; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID;

ADULT; AGED; ARTICLE; CATABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DIET; DIET SUPPLEMENTATION; FEMALE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

APOLIPOPROTEIN A-I; BIOLOGICAL TRANSPORT; DIABETES MELLITUS, TYPE 2; DIETARY FATS, UNSATURATED; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE;

EID: 0034971366     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00723-1     Document Type: Article

References (14)

1. The inverse relation between fish consumption and 20-year mortality from coronary heart disease
2. Effect of fish oil concentrate on lipoprotein composition in NIDDM
3. Effects of w-3 fatty acids on plasma lipids, cholesterol and lipoproteins fatty acid content in NIDDM patients
4. A comparison of fish oil or corn oil supplements in hyperlipidemic subjects with NIDDM
5. The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM: A randomized controlled study
6. Alterations in molecular species of cholesterol esters formed via lecithin-cholesterol acyltransferase in human subjects consuming fish oil
7. Effects of w 3 fish oil on lipid metabolism, glycemic control, and blood pressure in type II diabetic patients
8. Apolipoprotein B metabolism in hypertriglyceridemic diabetic patients administered either a fish oil- or vegetable oil-enriched diet
9. High density lipoprotein apolipoprotein AI kinetics in NIDDM: A stable isotope study
10. Increased apo AI and apo AII fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia
11. Plasma high density lipoprotein concentration and subfraction in relation to triglyceride metabolism
12. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance
13. Apolipoprotein AI and AII metabolism in patients with primary high density lipoprotein deficiency associated with familial hypertriglyceridemia
14. Human HDL cholesterol levels are determined by apo AI fractional catabolic rate, which correlates inversely with estimates of HDL particle size